ANGPTL4 and metabolic syndrome: The human Angptl4 E40K mutation can deactivate Angptl4, thereby reducing triglycerides, increasing high-density lipoprotein cholesterol, and reducing dyslipidemia and arteriosclerosis [37], as well as the incidence of cardiovascular disease [38].